Clinical Trials and Gynecological Cancer Patients
Links shared publicly online about this topic
Gynecologic Cancer Patients Should Consider Clinical Trials
medicalnewstoday.com — “For the estimated 83,000 women who will be diagnosed with a gynecologic cancer in 2010, participation in clinical trials offers an opportunity both to ensure that future patients benefit from the” View full resource at medicalnewstoday.com
Most Recently Shared on September 6, 2010 at 12:37 pm By:
Women's Health Line Health Site
Gynecologic Cancer Patients Should Consider Clinical Trials http://sns.ly/xSL49 #womenshealth
Health News - Gynecologic Cancer Patients Should Consider Clinical Trials
healthcanal.com — “Gynecologic Cancer Patients Should Consider Clinical Trials” View full resource at healthcanal.com
Most Recently Shared on September 7, 2010 at 12:00 pm By:
JanCerny, MD, PhD Hematologist, Physician, Doctor, PhD, Internist, and Oncologist
Gynecologic Cancer Patients Should Consider Clinical Trials http://ow.ly/2AhG9
ScienceDirect - Gynecologic Oncology : Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
sciencedirect.com — “ScienceDirect - Gynecologic Oncology : Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma” View full resource at sciencedirect.com
Most Recently Shared on May 31, 2011 at 4:30 am By:
Paul Cacciatore Patient Advocate
Mayo Clinic finds lapatinib + topotecan 4 treatment of plat. refrac/resist ovarian cancer lacks sufficient activity. http://dld.bz/abFdq
MabCure Launches Clinical Trial To Diagnose Ovarian Cancer
medicalnewstoday.com — “Mabcure, n.v. (mabcure) a wholly-owned subsidiary of mabcure inc. (otcbb: mbci) , a biotech company that has developed a series of highly specific monoclonal antibodies (mabs) to combat various ” View full resource at medicalnewstoday.com
Most Recently Shared on January 8, 2010 at 9:18 am By:
MabCure Launches Clinical Trial To Diagnose Ovarian Cancer http://mnt.to/3w47
Genentech initiates GDC-0449 Phase II clinical trial in BCC patients
buzzup.com — “Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).” View full resource at buzzup.com
Most Recently Shared on October 11, 2010 at 3:09 pm By:
Ovarian Cancer News: Genentech initiates GDC-0449 Phase II clinical trial in BCC patients: Curis, Inc. a drug d... http://buzzup.com/1cd3s
Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients With Platinum-Resistant Ovarian Cancer
medicalnewstoday.com — “Nektar Therapeutics (Nasdaq: NKTR) announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's” View full resource at medicalnewstoday.com
Most Recently Shared on October 29, 2009 at 12:28 pm By:
MNT Clinical Trials Health News
Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients With Pl.. http://bit.ly/1oFnQt
EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment
medicalnewstoday.com — “EGEN, Inc. announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The trial is sponsored by the Gynecologic” View full resource at medicalnewstoday.com
Most Recently Shared on December 15, 2010 at 6:05 pm By:
MNT Ovarian Cancer Health News
EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment http://mnt.to/3P6r #ovariancancer
FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer
news-medical.net — “Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.” View full resource at news-medical.net
Most Recently Shared on May 3, 2010 at 5:48 pm By:
Ovarian Cancer News: FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer: Tikcr... http://buzzup.com/vyot
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on May 28, 2011 at 4:45 pm By:
Paul Cacciatore Patient Advocate
Gyn Oncol Grp recruiting clear cell ovarian cancer patients for 1st line treatment w/temsirolimus + carbo + paclitaxel. http://dld.bz/ab589
Ovarian Cancer Drug Shows Promise With Move To Phase 3 Trial
medicalnewstoday.com — “A new drug designed to arrest cancer cell growth by inhibiting blood vessel formation in ovarian cancer patients is being readied for a phase 3 trial in Australia, Canada and Europe. The” View full resource at medicalnewstoday.com
Most Recently Shared on November 10, 2010 at 6:05 pm By:
MNT Ovarian Cancer Health News
Ovarian Cancer Drug Shows Promise With Move To Phase 3 Trial http://mnt.to/3MmS #ovariancancer
ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients
news-medical.net — “ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the initiation of a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.” View full resource at news-medical.net
Most Recently Shared on November 30, 2010 at 2:59 pm By:
Lung Cancer News: ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients: ImmunoGen, Inc., a bio... http://bit.ly/eaVV6y
Few Cancer Patients Participate In Clinical Trials // Pharmalot
pharmalot.com — “Few Cancer Patients Participate In Clinical Trials // Pharmalot” View full resource at pharmalot.com
Most Recently Shared on August 30, 2011 at 6:32 pm By:
ReedMedicalEducation Medical Education
RT @pharmalot: Few Cancer Patients Participate In Clinical Trials http://t.co/5S1iNT7
Few physicians refer patients to cancer clinical trials
physorg.com — “A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals, according to an online study published Feb. 11 in The Journal of the National Cancer Institute.” View full resource at physorg.com
Most Recently Shared on February 12, 2011 at 7:53 am By:
Few physicians refer patients to cancer clinical trials http://bit.ly/fK9vur
Few physicians refer patients to cancer clinical trials
sciencedaily.com — “A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals, according to an new study.” View full resource at sciencedaily.com
Most Recently Shared on February 16, 2011 at 7:42 pm By:
FasterCures Health Organization
Low proportion of cancer patients participate in clinical trials due to lack of physician referrals. http://bit.ly/fwsHCz
Few physicians refer patients to cancer clinical trials
eurekalert.org — “A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals, according to an online study published Feb. 11 in the Journal of the National Cancer Institute.” View full resource at eurekalert.org
Most Recently Shared on February 12, 2011 at 11:10 pm By:
NatureRevEndocrinol Endocrinology and Medical Journal
RT @bill_alford: National Cancer Institute-only 2% of newly diagnosed cancer patients participate in trial studies http://bit.ly/eZyc2p
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Women's Health Line
The latest women's health news and research.
-
JanCerny, MD, PhD
Assistant Professor, UMASS, HemOnc, BMT, Lymphoma, Leukemia
-
Paul Cacciatore
Founder of Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education)
Advertisement
